Propanc Biopharma, Inc.
Propanc Biopharma, Inc. is a development-stage biopharmaceutical company focused on creating cancer therapies based on pro-enzyme technology. Its lead candidate, PRP, is being developed for pancreatic, ovarian, and colorectal cancer, with operations centered in the United States and Australia through a parent company and wholly owned subsidiary structure.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaThe company's main therapeutic asset, a pro-enzyme formulation intended for cancer treatment.
Research-stage cancer programs targeting pancreatic, ovarian, and colorectal cancers.
Patent applications and allowances supporting future clinical development and exclusivity.
Asiakkaat
Propanc Biopharma does not currently sell commercial products; its near-term counterparties are research collaborators, scientific consultants, patent offices, and capital providers rather than end-market patients. If developed and approved, its therapies would be used by oncology specialists and healthcare systems treating high-risk cancer patients. The company’s business model is therefore centered on advancing a clinical asset toward future licensing or commercialization.
Universities, hospitals, and scientific partners that support preclinical studies and publication work.
Agencies and offices involved in patent allowance and future clinical/regulatory pathways.
Cancer specialists and healthcare systems that would use PRP if it reaches approval.
Investors and noteholders that fund ongoing development and corporate operations.
Strategia
Propanc’s strategy is to advance PRP through preclinical and eventual clinical development, supported by patent protection and external research collaborations. The company is also building an intellectual property position around dosage ranges and pro-enzyme composition to support future partnering or commercialization. Because it is pre-revenue, execution depends on scientific validation, regulatory progress, and access to funding.
Clinical proof is the main value-creation step for a preclinical oncology asset.
Patent protection supports exclusivity and future partnering leverage.
Academic and hospital partnerships help generate data and credibility.
Maantiede
The company is based in Camberwell, Victoria, Australia, while the parent entity is incorporated in Delaware in the United States. It also formed a UK subsidiary for a planned orphan-drug pathway in Europe, although that entity has remained inactive. The business is intended for global markets, but current activity is concentrated in Australia, the U.S., and selected research collaborations in Europe.
Riskit
The company faces the core risks of preclinical biotechnology: scientific failure, regulatory delay, and the possibility that its lead candidate never reaches commercialization. It also relies on external funding and equity-linked financing, which can create dilution and balance-sheet pressure, while patent and IP outcomes remain important to the long-term value proposition.
- Preclinical development failureVaikutus: Kriittinen
PRP has not yet demonstrated clinical efficacy or safety in humans.
Kohdistuu: Lead asset
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company has relied on convertible notes and equity issuances to fund operations.
Kohdistuu: Capital structure
- Going-concern and liquidity pressureVaikutus: KorkeaTodennäköisyys: Korkea
A pre-revenue development company must continually access external capital.
Kohdistuu: Corporate operations
- Regulatory and clinical delayVaikutus: Korkea
Drug development requires approvals, trials, and data generation before commercialization.
Kohdistuu: Clinical pathway
- Intellectual property uncertaintyVaikutus: Keskitaso
Patent scope, allowance, and enforceability affect future exclusivity and partnering value.
Kohdistuu: PRP and pro-enzyme composition
Kirjanpito
Harkinnanvaraiset erätLarge equity awards to officers, consultants, and service providers can materially inflate operating expense.
Vaikutus: Affects administration expense and non-cash dilution
Debt conversions, discounts, and related derivative liabilities require judgment and can create volatility.
Vaikutus: Affects liabilities, equity, and financing-related gains/losses
Shares issued for services, warrants, and other instruments depend on valuation assumptions.
Vaikutus: Affects expense recognition and equity balances
The company states it expects future royalties only when product sales occur and royalty terms begin.
Vaikutus: Currently no meaningful revenue, but future royalty timing will matter
Operations span U.S. and Australian entities, creating translation and exchange-rate effects.
Vaikutus: Affects consolidated results and equity
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Provectus Biopharmaceuticals, Inc.
PVCT · Pharmaceutical Preparations
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Prelude Therapeutics Inc
PRLD · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.\new
PTIX · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.
NuCana plc
NCNA · Pharmaceutical Preparations
NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer medicines based on its ProTide phosphoramidate chemistry platform.
Päivitetty: 24.9.2026